@article{153a57fa9bfb4516af7ba6cecb7f1d08,
title = "Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI",
abstract = "Objective To examine whether the use of sex-specific norms and cut scores to identify memory impairment improves diagnostic accuracy of amnestic mild cognitive impairment (aMCI) compared to non-sex-specific (typical) norms/cut scores given the female advantage in verbal memory. Methods We calculated sex-specific and typical norms/cut scores (age and education specific) for impairment on the Rey Auditory Verbal Learning Test in the Mayo Clinic Study of Aging. Norms/cut scores were applied to 453 women and 532 men from the Alzheimer's Disease Neuroimaging Initiative. We compared sex differences in rates of aMCI (Jak/Bondi criteria) for sex-specific vs typical norms/cut scores. Using sex-specific cut scores as the true condition and typical cut scores as the predicted condition, we categorized participants as true positives (TPs), false positives (FPs), true negative (TNs), or false negative (FNs). In cross-sectional analyses within sex, we compared positivity rates of CSF hyperphosphorylated tau/β-amyloid (Aβ) and cortical Aβ deposition ([18F]AV45 PET) and APOE e4 frequency among diagnostic comparison groups. Results The frequency of aMCI was higher in men when using typical norms/cut scores. Using sex-adjusted norms/cut scores led to the identification of 10% FNs (missed aMCI cases) among women and 10% FPs among men. Biomarker analyses supported the hypothesis that sex-specific diagnostic criteria improves diagnostic accuracy. Biomarkers rates were higher in FNs vs TNs and similar in FNs and TPs. Biomarker rates were lower in FPs vs TPs and similar between FPs and TNs. Conclusion Results suggest that non-sex-specific aMCI diagnostic criteria led to a 20% diagnostic error rate. Accounting for sex differences in verbal memory performance may improve aMCI classification.",
author = "{Alzheimer's Disease Neuroimaging Initiative} and Sundermann, {Erin E.} and Pauline Maki and Anat Biegon and Lipton, {Richard B.} and Mielke, {Michelle M.} and Mary Machulda and Bondi, {Mark W.}",
note = "Funding Information: This work was supported by the NIH (grants AG049810, AG05131, K24 AG026431, U01 AG006786, RF1 AG55151, U54 AG44170). Data collection and sharing for this project were funded by the ADNI (NIH grant U01 AG024904) and Department of Defense ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, by the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Co; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Co; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Co; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Dr. Lipton's time was supported by funding for the Einstein Aging Study: National Institute on Aging grants AG003949, AG026728, TL1RR000087, and T32-GM007288. Funding Information: E. Sundermann reports no disclosures relevant to the manuscript. P. Maki has received speaking honorarium from Mylan. A. Biegon reports no disclosures relevant to the manuscript. R. Lipton reports research support from the NIH: 2PO1 AG003949 (program director), 5U10 NS077308 (principal investigator [PI]), RO1 NS082432 (investigator), 1RF1 AG057531 (site PI), RF1 AG054548 (investigator), 1RO1 AG048642 (investigator), R56 AG057548 (investigator), K23 NS09610 (mentor), K23AG049466 (mentor), and 1K01AG054700 (mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, as senior advisor to Headache, and as associate editor to Cephalalgia. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; holds stock options in eNeura Therapeutics and Biohaven Holdings; and serves as consultant or advisory board member or has received honoraria from the American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Bio-vision, Boston Scientific, Dr. Reddy{\textquoteright}s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff{\textquoteright}s Headache , 7th and 8th editions, Oxford Press University, Wiley, and Informa. M. Mielke and M. Machulda report no disclosures relevant to the manuscript. M. Bondi is paid royalties from Oxford University Press and serves as a consultant for Eisai and Novartis. Go to Neurology.org/N for full disclosures. Funding Information: This work was supported by the NIH (grants AG049810, AG05131, K24 AG026431, U01 AG006786, RF1 AG55151, U54 AG44170). Data collection and sharing for this project were funded by the ADNI (NIH grant U01 AG024904) and Department of Defense ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, by the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Co; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Co; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Co; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Dr. Lipton{\textquoteright}s time was supported by funding for the Einstein Aging Study: National Institute on Aging grants AG003949, AG026728, TL1RR000087, and T32-GM007288. Publisher Copyright: Copyright {\textcopyright} 2019 American Academy of Neurology.",
year = "2019",
month = nov,
day = "12",
doi = "10.1212/WNL.0000000000008467",
language = "English (US)",
volume = "93",
pages = "E1881--E1889",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",
}